Combination therapy strategies are being actively explored to overcome resistance and enhance efficacy: Combining MET inhibitors with chemotherapy (e.g., fluorouracil, leucovorin, and oxaliplatin in the mFOLFOX6 regimen) has shown synergistic effects in some studies, as chemotherapy may help target resistant tumor subclones while maintaining selective MET inhibition (50).MET amplification is often associated with an immunosuppressive tumor microenvironment, suggesting a potential role for immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapy) in combination with MET-targeted therapy. The gene discussed is MET; the disease is neoplasm.